- Home
- STRO vs CDLX Comparison
STRO vs CDLX Comparison
Compare STRO & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- CDLX
- Stock Information
- Founded
- STRO 2003
- CDLX 2008
- Country
- STRO United States
- CDLX United States
- Employees
- STRO 306
- CDLX N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- CDLX Computer Software: Programming Data Processing
- Sector
- STRO Health Care
- CDLX Technology
- Exchange
- STRO Nasdaq
- CDLX Nasdaq
- Market Cap
- STRO 165.7M
- CDLX 180.4M
- IPO Year
- STRO 2018
- CDLX 2018
- Fundamental
- Price
- STRO $2.01
- CDLX $3.16
- Analyst Decision
- STRO Strong Buy
- CDLX Hold
- Analyst Count
- STRO 7
- CDLX 6
- Target Price
- STRO $12.14
- CDLX $5.90
- AVG Volume (30 Days)
- STRO 984.3K
- CDLX 932.4K
- Earning Date
- STRO 11-13-2024
- CDLX 03-13-2025
- Dividend Yield
- STRO N/A
- CDLX N/A
- EPS Growth
- STRO N/A
- CDLX N/A
- EPS
- STRO N/A
- CDLX N/A
- Revenue
- STRO $160,955,000.00
- CDLX $293,468,000.00
- Revenue This Year
- STRO N/A
- CDLX N/A
- Revenue Next Year
- STRO N/A
- CDLX $3.49
- P/E Ratio
- STRO N/A
- CDLX N/A
- Revenue Growth
- STRO 230.90
- CDLX N/A
- 52 Week Low
- STRO $1.67
- CDLX $2.76
- 52 Week High
- STRO $6.13
- CDLX $20.52
- Technical
- Relative Strength Index (RSI)
- STRO 46.47
- CDLX 40.53
- Support Level
- STRO $1.72
- CDLX $2.76
- Resistance Level
- STRO $2.15
- CDLX $3.92
- Average True Range (ATR)
- STRO 0.14
- CDLX 0.26
- MACD
- STRO 0.05
- CDLX -0.05
- Stochastic Oscillator
- STRO 70.83
- CDLX 33.87
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About CDLX Cardlytics Inc.
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K., and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.